MX383904B - Métodos y composiciones para restablecer la función de p53 mutante. - Google Patents

Métodos y composiciones para restablecer la función de p53 mutante.

Info

Publication number
MX383904B
MX383904B MX2018009947A MX2018009947A MX383904B MX 383904 B MX383904 B MX 383904B MX 2018009947 A MX2018009947 A MX 2018009947A MX 2018009947 A MX2018009947 A MX 2018009947A MX 383904 B MX383904 B MX 383904B
Authority
MX
Mexico
Prior art keywords
compounds
mutant
methods
function
restoring
Prior art date
Application number
MX2018009947A
Other languages
English (en)
Spanish (es)
Other versions
MX2018009947A (es
Inventor
Binh Vu
Hongju Li
Romyr Dominique
Original Assignee
Pmv Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pmv Pharmaceuticals Inc filed Critical Pmv Pharmaceuticals Inc
Publication of MX2018009947A publication Critical patent/MX2018009947A/es
Publication of MX383904B publication Critical patent/MX383904B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2018009947A 2016-02-19 2017-02-17 Métodos y composiciones para restablecer la función de p53 mutante. MX383904B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662297450P 2016-02-19 2016-02-19
PCT/US2017/018511 WO2017143291A1 (en) 2016-02-19 2017-02-17 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Publications (2)

Publication Number Publication Date
MX2018009947A MX2018009947A (es) 2019-01-21
MX383904B true MX383904B (es) 2025-03-14

Family

ID=59625486

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009947A MX383904B (es) 2016-02-19 2017-02-17 Métodos y composiciones para restablecer la función de p53 mutante.

Country Status (10)

Country Link
US (4) US10138219B2 (enExample)
EP (1) EP3416638A4 (enExample)
JP (1) JP6956098B2 (enExample)
KR (1) KR102868217B1 (enExample)
CN (2) CN109069481A (enExample)
AU (1) AU2017221472B2 (enExample)
CA (2) CA3010847C (enExample)
IL (2) IL286839B (enExample)
MX (1) MX383904B (enExample)
WO (1) WO2017143291A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6956098B2 (ja) 2016-02-19 2021-10-27 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド 変異体ｐ５３機能を復元させるための方法および化合物
PH12022550707A1 (en) 2019-09-23 2023-03-27 Pmv Pharmaceuticals Inc METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
WO2021231474A1 (en) * 2020-05-12 2021-11-18 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
CN113750246B (zh) * 2020-06-04 2023-12-05 华南理工大学 ZIF-8纳米材料在降解广谱突变p53蛋白中的应用
CN111686127B (zh) * 2020-06-04 2022-02-15 华南理工大学 锌铁纳米材料在降解突变p53蛋白中的应用
WO2021262684A1 (en) * 2020-06-22 2021-12-30 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
US20230024905A1 (en) * 2020-06-22 2023-01-26 Pmv Pharmaceuticals, Inc. Uses of p53 x-ray co-crystal structures
EP4167982A4 (en) * 2020-06-22 2024-08-07 PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING FUNCTION OF P53 MUTANTS
CN116249689A (zh) * 2020-06-24 2023-06-09 皮姆维制药公司 用于再激活突变p53的化合物的伴随诊断工具
WO2021262483A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
MX2022015793A (es) * 2020-06-24 2023-02-27 Pmv Pharmaceuticals Inc Terapia de combinacion para tratamiento de cancer.
EP4267553A1 (en) 2020-12-24 2023-11-01 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x2 and related products and methods
WO2022213975A1 (en) * 2021-04-08 2022-10-13 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
TW202322796A (zh) * 2021-08-10 2023-06-16 大陸商北京加科思新藥研發有限公司 靶向p53突變體的化合物
WO2023025324A1 (zh) * 2021-08-27 2023-03-02 杭州紫晶医药科技有限公司 作为p53调节剂的化合物
CN118891041A (zh) 2022-01-27 2024-11-01 皮姆维制药公司 用于恢复突变p53功能的氘代化合物
WO2024017384A1 (zh) * 2022-07-22 2024-01-25 深圳众格生物科技有限公司 恢复p53突变功能的化合物及其应用
WO2024041503A1 (en) * 2022-08-22 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
CN120077047A (zh) * 2022-10-21 2025-05-30 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
WO2024120471A1 (en) * 2022-12-08 2024-06-13 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting mutant of p53
WO2025031471A1 (zh) * 2023-08-09 2025-02-13 德睿智药(苏州)新药研发有限公司 用于调节p53功能的新型杂环类化合物
CN119350323B (zh) * 2023-10-20 2025-06-13 上海宇道生物技术有限公司 一类靶向p53突变的N-磺酰酰胺含氮稠杂环类化合物及其应用
WO2025242903A1 (en) * 2024-05-24 2025-11-27 Onco3R Therapeutics Bv Compounds and pharmaceutical compositions thereof for the treatment of proliferative diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003326B1 (ru) * 1998-12-02 2003-04-24 Пфайзер Продактс Инк. Способ лечения рака
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
EP1689710A1 (en) 2003-11-25 2006-08-16 Novo Nordisk A/S Indole derivatives for use as chemical uncoupler
JP2008505910A (ja) 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
WO2009112075A1 (en) * 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
KR20160067981A (ko) * 2008-04-16 2016-06-14 카로 바이오 아베 신규한 에스트로겐 수용체 리간드
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
PL2410844T3 (pl) 2009-03-27 2016-08-31 Merck Sharp & Dohme Inhibitory replikacji wirusa zapalenia wątroby typu c
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
EP2665707B1 (en) 2011-01-20 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
GB201110390D0 (en) * 2011-06-20 2011-08-03 Medical Res Council Compounds for use in stabilising p53 mutants
WO2013036208A1 (en) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
US8859780B2 (en) 2011-12-28 2014-10-14 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
US8822689B2 (en) 2012-09-19 2014-09-02 Merial Limited Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
JP6427599B2 (ja) * 2014-05-19 2018-11-21 チャンスー ヘンルイ メディシン カンパニー，リミテッド チロシンキナーゼ阻害剤としての置換エチニルヘテロ二環式化合物
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
JP6956098B2 (ja) 2016-02-19 2021-10-27 ピーエムブイ ファーマシューティカルズ， インコーポレイテッド 変異体ｐ５３機能を復元させるための方法および化合物

Also Published As

Publication number Publication date
CN109069481A (zh) 2018-12-21
CN119161324A (zh) 2024-12-20
US20220213062A1 (en) 2022-07-07
WO2017143291A1 (en) 2017-08-24
JP6956098B2 (ja) 2021-10-27
EP3416638A4 (en) 2019-07-17
BR112018016890A2 (pt) 2019-02-12
US11339141B2 (en) 2022-05-24
KR20180138200A (ko) 2018-12-28
IL286839B (en) 2022-08-01
AU2017221472A1 (en) 2018-07-26
AU2017221472B2 (en) 2023-01-05
US20170240525A1 (en) 2017-08-24
MX2018009947A (es) 2019-01-21
US20190119249A1 (en) 2019-04-25
US10640485B2 (en) 2020-05-05
CN119161324B (zh) 2025-10-17
JP2019512465A (ja) 2019-05-16
EP3416638A1 (en) 2018-12-26
CA3215564A1 (en) 2017-08-24
US20210002252A1 (en) 2021-01-07
IL261175A (en) 2018-10-31
IL286839A (en) 2021-10-31
CA3010847A1 (en) 2017-08-24
IL261175B (en) 2021-10-31
KR102868217B1 (ko) 2025-10-14
CA3010847C (en) 2025-09-23
US10138219B2 (en) 2018-11-27

Similar Documents

Publication Publication Date Title
MX383904B (es) Métodos y composiciones para restablecer la función de p53 mutante.
MX2022003456A (es) Metodos y compuestos para restaurar la funcion del mutante p53.
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CL2018000955A1 (es) Terapia de combinación para el tratamiento de neoplasias malignas
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CL2019000061A1 (es) Anticuerpo para anti-claudin 18a2 y su utilización.
CY1120035T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
UY37141A (es) Anticuerpos dirigidos a tigit
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
CO2017010618A2 (es) Anticuerpos contra icos
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
MX2022015794A (es) Herramienta complementaria de diagnostico para compuestos reactivantes p53 mutantes.
DOP2017000111A (es) Inhibidor de cinasa aurora a
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
UY36351A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EA201691376A1 (ru) Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
CL2018000371A1 (es) Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral.
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
CY1122229T1 (el) Μεθοδοι και υλικα για την αντιμετωπιση αιματολογικων κακοηθειων
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv